Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Burkitt Lymphoma 27Neoplasm, Residual 13Leukemia 6Recurrence 5Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphoid 3Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Blast Crisis 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid 1Leukemia, Large Granular Lymphocytic 1Leukemia, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

fludarabine 9Cytarabine 9venetoclax 5fludarabine phosphate 5Cyclophosphamide 5Busulfan 5thymoglobulin 4Tacrolimus 4Sirolimus 4Mycophenolic Acid 4Methotrexate 4Azacitidine 4aldesleukin 3Whole-Body Irradiation 3Interleukin-2 3Antilymphocyte Serum 3asciminib 2Thiotepa 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Dasatinib 2Cyclosporine 2Bone Marrow Transplantation 2Blood Specimen Collection 2Behavior Therapy 2zileuton 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid × blinatumomab × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡